1-5 of 5
Gerard Zalcman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates

Filippo G. Dall’Olio, Wael Zrafi, Veronique Roelants, Valentina Ambrosini, Aloyse Fourquet, Cristina Mitea, Francesco Passiglia, Matteo Bauckneht, Gerald Bonardel, Nicole Conci, Jose Carlos Benitez, Vincenzo Arena, Céline Namour, Marie Naigeon, Isabelle Monnet, Kristi Beshiri, Delphine Hoton, Safiye Dursun, François Xavier Danlos, Giulia Argalia, Mihaela Aldea, Guido Rovera, Lisa Derosa, Valerio Iebba, Hester A. Gietema, Valerie Gounant, Valérie Lacroix, Jordi Remon, Daniel Gautheret, Nathalie Chaput, Bastien Job, Patricia L. Kannouche, Monica Velasco-Nuño, Laurence Zitvogel, Eugenia Cella, José Reinaldo Chícharo de Freitas, Damien Vasseur, Mohamed Aymen Bettaieb, Marco Tagliamento, Lizza Hendriks, Antoine Italiano, David Planchard, Aurelien Marabelle, Fabrice Barlesi, Silvia Novello, Desiree De Andreis, Frank Aboubakar Nana, Andrea Ardizzoni, Gerard Zalcman, Camilo Garcia, Benjamin Besse
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2): 352–364.
https://doi.org/10.1158/1078-0432.CCR-24-1993
Published: 17 January 2025
View article titled, Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates
Open the PDF for Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial

Julien Mazieres, Fabrice Barlesi, Isabelle Rouquette, Olivier Molinier, Benjamin Besse, Isabelle Monnet, Clarisse Audigier-Valette, Anne-Claire Toffart, Patrick Aldo Renault, Séverine Fraboulet, Sandrine Hiret, Bertrand Mennecier, Didier Debieuvre, Virginie Westeel, Philippe Masson, Anne Madroszyk-Flandin, Eric Pichon, Alexis B. Cortot, Elodie Amour, Franck Morin, Gérard Zalcman, Denis Moro-Sibilot, Pierre-Jean Souquet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3172–3181.
https://doi.org/10.1158/1078-0432.CCR-19-3056
Published: 01 July 2020
View article titled, Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial
Open the PDF for Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial in another window
Journal Articles

Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

Guillaume Eberst, Amélie Anota, Arnaud Scherpereel, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, Hervé Léna, Frédéric Rivière, Isabelle Monnet, Valérie Gounant, Henri Janicot, Radj Gervais, Chrystelle Locher, Emilie Charton, Franck Morin, Gérard Zalcman, Virginie Westeel
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5759–5765.
https://doi.org/10.1158/1078-0432.CCR-18-2860
Published: 01 October 2019
View article titled, Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial
Open the PDF for Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial in another window
Includes: Supplementary data
Journal Articles

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

Sébastien Couraud, Felipe Vaca-Paniagua, Stéphanie Villar, Javier Oliver, Tibor Schuster, Hélène Blanché, Nicolas Girard, Jean Trédaniel, Laurent Guilleminault, Radj Gervais, Nathalie Prim, Michel Vincent, Jacques Margery, Sébastien Larivé, Pascal Foucher, Bernard Duvert, Maxime Vallee, Florence Le Calvez-Kelm, James McKay, Pascale Missy, Franck Morin, Gérard Zalcman, Magali Olivier, Pierre-Jean Souquet
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4613–4624.
https://doi.org/10.1158/1078-0432.CCR-13-3063
Published: 01 September 2014
View article titled, Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002
Open the PDF for Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 in another window
Includes: Supplementary data
Journal Articles

An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

Florence de Fraipont, Guénaëlle Levallet, Christian Creveuil, Emmanuel Bergot, Michèle Beau-Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie-Christine Favrot, Didier Debieuvre, Denis Braun, Virginie Westeel, Elisabeth Quoix, Elisabeth Brambilla, Pierre Hainaut, Denis Moro-Sibilot, Franck Morin, Bernard Milleron, Gérard Zalcman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10): 2976–2986.
https://doi.org/10.1158/1078-0432.CCR-11-2797
Published: 14 May 2012
View article titled, An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
Open the PDF for An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial in another window
Includes: Supplementary data